Neurocrine Bioscienc (NBIX) Stock Price, Quote & News

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 858 617 7600

Website: www.neurocrine.com

Address:

6027 Edgewood Bend Court, San Diego, United States

Wolfofwits Aug. 13 at 8:52 PM

$NBIS double down on $NBIX CSP $5 Have a .40 premium still

1 · Reply

FannyPackin Aug. 13 at 6:23 PM

$NBIX bought 151.69 today.. will add more if keeps dropping

2 · Reply

GoIrish1776 Aug. 13 at 1:39 PM

$NBIX Silver lining is those August covered calls I sold are going to expire. Win-win. The company will figure out how to sell Vykat. Their sales org is excellent. It may be the company’s greatest asset beyond Ingrezza and Crenessity themselves.

1 · Reply

TNNStockAnalysisNews Aug. 13 at 6:07 AM

Top Stock Losers Today — August 12 $NCMI — Down 31% Despite a $275M Acquisition Announcement $NBIX — Falls Up to 5.8% on Drug Safety Concerns $OKLO — Falls 4% Even After a Positive “Criticality” Milestone $PFGC — Slips 5% on Guidance Miss $NVO — Falls 3.4% on a Berenberg Downgrade https://truthsandnews.com/markets/top-stock-losers-today-august-12-2026-ncmi

0 · Reply

StocktwitsNews Aug. 12 at 11:42 PM

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings $NBIX $JGRO $AVUS https://stocktwits.com/news/equity/markets/nbix-stock-slips-as-2-9-b-soleno-deal-triggers-fresh-drug-safety-warnings/cZo8lijRJWD

0 · Reply

outlawinvestor1 Aug. 12 at 9:28 PM

$NBIX $SLNO not surprised by this - i always thought vykat/soleno was a bad drug and investment. https://www.biospace.com/drug-development/deaths-reported-after-treatment-with-neurocrines-approved-prader-willi-drug

0 · Reply

notreload_ai Aug. 12 at 7:46 PM

$NBIX reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR. https://notreload.xyz/xy/neurocrine-ingrezza-gains-meet-vykat-xr-safety-concerns/

0 · Reply

GoIrish1776 Aug. 12 at 1:38 PM

$NBIX “The statement emphasizes that these reports do not establish that VYKAT XR caused these outcomes. Many of the individuals involved had complex medical conditions, multiple medications, severe obesity, or other significant health challenges that are unfortunately common within the PWS population. The reality is that people with PWS already face a higher risk of serious respiratory and cardiac complications throughout their lives.”

0 · Reply

SternInvesting10 Aug. 12 at 12:57 PM

$NBIX that’s fucking great you acquire a company for billions and then their drug doesn’t even work and has massive adverse effects.

1 · Reply

OpenOutcrier Aug. 12 at 12:49 PM

$NBIX (-5.9% pre) Neurocrine slips on safety issues linked to Vykat XR https://ooc.bz/l/110979

0 · Reply

Neurocrine announces INECT-PRO Phase 4 open-label study results

2026-08-17T08:34:50.000Z - 1 day ago

Neurocrine price target lowered to $165 from $190 at Deutsche Bank

2026-08-17T08:01:18.000Z - 1 day ago

Neurocrine price target lowered to $182 from $196 at Morgan Stanley

2026-08-17T07:56:15.000Z - 1 day ago

Neurocrine price target lowered to $218 from $221 at Bernstein

Aug 12, 2026, 8:30 AM EDT - 6 days ago

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Aug 12, 2026, 7:12 AM EDT - 6 days ago

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

2026-08-07T12:36:25.000Z - 11 days ago

Neurocrine initiates Phase 1 study of NBIP-‘1968

Aug 7, 2026, 8:30 AM EDT - 11 days ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

2026-08-03T12:20:46.000Z - 15 days ago

Neurocrine price target raised to $194 from $185 at Wedbush

2026-08-03T11:16:19.000Z - 15 days ago

Neurocrine price target raised to $210 from $200 at Canaccord

2026-07-31T17:35:18.000Z - 18 days ago

Neurocrine price target raised to $249 from $246 at Citi

2026-07-31T15:15:51.000Z - 18 days ago

Wells Fargo recommends buying Neurocrine on weakness after solid quarter

2026-07-31T13:11:37.000Z - 18 days ago

Neurocrine price target raised to $196 from $193 at Morgan Stanley

2026-07-31T13:02:18.000Z - 18 days ago

Neurocrine price target raised to $220 from $200 at TD Cowen

2026-07-31T12:56:26.000Z - 18 days ago

Neurocrine price target raised to $190 from $170 at Deutsche Bank

2026-07-31T12:37:18.000Z - 18 days ago

Neurocrine price target raised to $214 from $199 at BofA

2026-07-31T12:25:57.000Z - 18 days ago

Neurocrine price target raised to $215 from $210 at Cantor Fitzgerald

2026-07-31T11:53:06.000Z - 18 days ago

Neurocrine price target raised to $204 from $200 at Needham

2026-07-31T11:35:47.000Z - 18 days ago

Neurocrine price target raised to $210 from $207 at Piper Sandler

2026-07-31T11:26:31.000Z - 18 days ago

Neurocrine price target raised to $225 from $186 at Baird

2026-07-31T11:26:25.000Z - 18 days ago

Neurocrine price target raised to $215 from $188 at Stifel

2026-07-31T10:55:54.000Z - 18 days ago

Neurocrine price target raised to $222 from $200 at Guggenheim

Jul 30, 2026, 4:30 PM EDT - 18 days ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 18 days ago

Neurocrine Biosciences Earnings release: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 18 days ago

Neurocrine Biosciences Slides: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 18 days ago

Neurocrine Biosciences Quarterly report: Q2 2026

Jul 30, 2026, 4:01 PM EDT - 18 days ago

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Jul 23, 2026, 4:05 PM EDT - 25 days ago

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Jul 21, 2026, 4:05 PM EDT - 27 days ago

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

Jul 10, 2026, 11:58 AM EDT - 5 weeks ago

Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline

Jul 9, 2026, 4:01 PM EDT - 5 weeks ago

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Jul 1, 2026, 4:05 PM EDT - 6 weeks ago

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Jun 15, 2026, 4:10 PM EDT - 2 months ago

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

PWS

Jun 15, 2026, 4:05 PM EDT - 2 months ago

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

CAH

Jun 15, 2026, 8:35 AM EDT - 2 months ago

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

Jun 15, 2026, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Neurocrine Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 4:05 PM EDT - 2 months ago

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

Jun 8, 2026, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Jun 2, 2026, 11:40 AM EDT - 2 months ago

Neurocrine Biosciences Transcript: 46th Annual William Blair Growth Stock Conference

May 26, 2026, 4:01 PM EDT - 2 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

May 18, 2026, 4:05 PM EDT - 3 months ago

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

May 18, 2026, 8:46 AM EDT - 3 months ago

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

May 14, 2026, 7:00 AM EDT - 3 months ago

4basebio Announces Appointment of Chief Financial Officer and Board Changes

MREO

May 12, 2026, 2:20 PM EDT - 3 months ago

Neurocrine Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

May 5, 2026, 4:30 PM EDT - 3 months ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Neurocrine Biosciences Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Neurocrine Biosciences Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Neurocrine Biosciences Slides: Q1 2026

May 5, 2026, 4:01 PM EDT - 3 months ago

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

May 5, 2026, 9:00 AM EDT - 3 months ago

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

May 4, 2026, 8:30 AM EDT - 3 months ago

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

May 4, 2026, 7:30 AM EDT - 3 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

May 1, 2026, 4:05 PM EDT - 3 months ago

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

Apr 29, 2026, 4:05 PM EDT - 3 months ago

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

Apr 22, 2026, 4:05 PM EDT - 4 months ago

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Neurocrine Biosciences Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Neurocrine Biosciences Proxy statement: Proxy filing

Apr 14, 2026, 4:01 PM EDT - 4 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

Apr 14, 2026, 8:30 AM EDT - 4 months ago

Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

Apr 12, 2026, 7:30 PM EDT - 4 months ago

Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

Apr 7, 2026, 1:17 PM EDT - 4 months ago

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

SLNO

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Neurocrine Biosciences Transcript: M&A announcement

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Neurocrine Biosciences Press release: M&A announcement

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Neurocrine Biosciences Slides: M&A announcement

Apr 6, 2026, 7:34 AM EDT - 4 months ago

Neurocrine to Buy Soleno for $2.9 Billion

SLNO

Apr 6, 2026, 7:24 AM EDT - 4 months ago

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.

Apr 6, 2026, 7:07 AM EDT - 4 months ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

SLNO

Apr 6, 2026, 7:04 AM EDT - 4 months ago

Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move.

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

SLNO

Mar 26, 2026, 8:30 AM EDT - 5 months ago

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Mar 17, 2026, 4:30 PM EDT - 5 months ago

Neurocrine Biosciences Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 4:05 PM EDT - 5 months ago

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

Mar 10, 2026, 4:01 PM EDT - 5 months ago

Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

Mar 9, 2026, 8:40 AM EDT - 5 months ago

Neurocrine Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 5:00 PM EST - 5 months ago

BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)

EFX

Mar 3, 2026, 11:50 AM EST - 6 months ago